CBER head Peter Marks weighs in on cell, gene therapy pricing debate – BioWorld Online
|
CBER head Peter Marks weighs in on cell, gene therapy pricing debate
BioWorld Online DUBLIN – Last week Philadelphia-based Spark Therapeutics Inc. reported $2.4 million revenue for the debut quarter of Luxturna (voretigene neparvovec-rzyl), its gene therapy for an inherited form of vision loss, which gained FDA approval last year … |
